METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Clinical trials for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER explained in plain language.
Never miss a new study
Get alerted when new METASTATIC CASTRATION-RESISTANT PROSTATE CANCER trials appear
Sign up with your email to follow new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo for tough prostate cancer shows early promise, but trial halted
Disease control TerminatedThis early-phase study tested a combination of two oral drugs, abemaciclib and darolutamide, in 10 men with metastatic castration-resistant prostate cancer that had spread despite standard hormone therapy. The main goal was to check safety and side effects. The trial was terminat…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New prostate cancer combo trial ends early
Disease control TerminatedThis study tested a new drug called exicorilant (CORT125281) combined with enzalutamide in men with metastatic castration-resistant prostate cancer. The goal was to find a safe dose and check for side effects. The trial was terminated early, so results are limited. It involved 39…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Corcept Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Cancer drug combo trial halted early after only 13 patients
Disease control TerminatedThis study tested a drug called zenocutuzumab combined with other medicines in people with two types of cancer: non-small cell lung cancer with a specific gene change (NRG1 fusion) and advanced prostate cancer that no longer responds to hormone therapy. The goal was to see if the…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Partner Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Promising prostate cancer combo trial stalls after just 7 patients
Disease control TerminatedThis phase II trial tested two drugs—denosumab and enzalutamide—together in men with advanced prostate cancer that no longer responds to hormone therapy and has spread to the bones. The goal was to see if the combination could slow cancer growth better than enzalutamide alone. Ho…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Cancer Trials Ireland • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Experimental prostate cancer pill put to the test
Disease control TerminatedThis early-stage study tested a new drug called TQB3720 in 192 men with advanced prostate cancer that had stopped responding to hormone therapy. The main goal was to find a safe dose and see how the drug moves through the body. The study was stopped early, so results are limited.
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Promising combo for prostate cancer falls short: trial ends early
Disease control TerminatedThis study tested a new drug, tazemetostat, combined with standard hormone therapies (enzalutamide or abiraterone/prednisone) in men with advanced prostate cancer that no longer responds to hormone therapy alone. The goal was to see if the combination could slow cancer growth bet…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Epizyme, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat prostate cancer
Disease control TerminatedThis early-stage study tested a new treatment called BPX-601 for people with advanced prostate cancer that had stopped responding to other therapies. The treatment uses a patient's own immune cells, modified to recognize and attack cancer cells carrying a specific marker (PSCA). …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Promising prostate cancer treatment trial halted early
Disease control TerminatedThis phase 3 study tested a radioactive antibody called 177Lu-DOTA-rosopatamab combined with standard care for men with metastatic castration-resistant prostate cancer that had progressed after hormone therapy. The goal was to see if the combination slowed cancer growth or improv…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE3 • Sponsor: Telix Pharmaceuticals (Innovations) Pty Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New drug combo for Hard-to-Treat cancers shows early promise but trial halted
Disease control TerminatedThis early-stage trial tested a new drug called RP-3467, alone or with olaparib, in 26 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. The study was terminated, so full results are no…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Repare Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Cancer drug combo trial halted early – what we know
Disease control TerminatedThis trial tested a combination of two drugs, rucaparib and atezolizumab, in 130 adults with advanced solid tumors that have specific DNA repair problems or are sensitive to platinum chemotherapy. The goal was to see if the combination could shrink tumors. However, the study was …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Promising cancer combo trial halted early
Disease control TerminatedThis study tested a new drug called SOT101 (nanrilkefusp alfa) combined with pembrolizumab in 166 people with advanced solid tumors like lung, colon, and ovarian cancer. The goal was to see if the combo could shrink tumors. The trial was stopped early, so results are limited.
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: SOTIO Biotech AG • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New cancer drug trial halted early – what we know
Disease control TerminatedThis early-stage trial tested an experimental drug called NUV-868, alone or with other cancer drugs, in 82 adults with advanced solid tumors (including ovarian, pancreatic, prostate, and breast cancers). The goal was to find safe doses and check for early signs of effectiveness. …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Nuvation Bio Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New drug targets Hard-to-Treat prostate cancer in early trial
Disease control TerminatedThis early-phase study tested a new drug called acapatamab in 212 men with advanced prostate cancer that had stopped responding to standard hormone therapy and chemotherapy. The drug works by helping the body's immune cells attack cancer cells. The main goals were to check safety…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Amgen's master trial for Hard-to-Treat prostate cancer hits early hurdles
Disease control TerminatedThis master trial tested several drug combinations, including a new targeted therapy called acapatamab, in 65 men with metastatic castration-resistant prostate cancer (mCRPC). The goal was to check safety and early signs of effectiveness. The study was terminated early, so result…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New pill for advanced prostate cancer shows early promise, but trial halted
Disease control TerminatedThis study tested an oral drug called LAE001 in 33 men with metastatic prostate cancer that had stopped responding to standard hormone therapy. The goal was to check safety and find the right dose, and to see if the drug could lower PSA levels. The trial was terminated early, so …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Laekna Limited • Aim: Disease control
Last updated Jun 26, 2026 15:36 UTC